pattyz
09-01-2005, 06:24 AM
Not just a clarification but an apology to Steph and anyone who read what I posted to her down the page here about the response rates of Temodar/Xeloda.
And and and....I can't remember if I posted this info before. very large <<sigh>> here.
ok. here it is and you can especially note the "RESULTS:" ( CR= complete response PR= partial response SD= stable disease MD=mixed response )
SABCS ABSTRACT: [San Antonio Breast Cancer Symposium] [1079] Phase I
study of capecitabine © in combination with temozolomide (T) in the
treatment of patients with brain metastases from breast carcinoma.
Rivera E, Valero V, Francis D, Brewster A, Royce M, Esteva F, Murray JL,
Pusztai L, Hortobagyi GN.. The University of Texas M.D. Anderson Cancer
Center, Houston, TX
Background: T is an oral alkylating agent that is currently being used
for the treatment of primary brain tumors due to its ability to cross
the blood-brain barrier. C has been approved for use in the treatment of
metastatic breast cancer patients who have failed anthracyclines and
taxanes. It is well known that C crosses the blood-brain barrier and has
activity in the brain. Options are limited for patients with brain
metastases.
Materials and Methods: We evaluated the activity of both drugs in
combination for the treatment of brain metastases not amenable to
surgery. Patients were allowed in the study if they had new onset brain
metastases from breast cancer, had declined radiation therapy, and were
neurologically stable. They were also eligible if they had evidence of
recurrence or progression of brain metastases after whole brain or
stereotactic radiation therapy. C was started at 1800
mg/m2 in 2 divided doses. T was given at a starting dose of 75 mg/m2 in
one daily dose. Each drug was given concomitantly every day for 5
days (day 1-5) followed by 2 days of rest and restarted again for an
additional 5 days (days 8-12). Each cycle was repeated every 21
days. We have enrolled a total of 16 pts — 6 pts at dose level 0
(C/T — 1800/75), 6 pts at dose level 1 (C/T — 1800/100), and 4 pts
at dose level 2
(n/T — 2000/100).
Results: Five pts had recurrent brain metastases and had been previously
treated with radiation therapy. The median age is 51 yrs (range, 32-77).
All pts had a Zubrod performance status < 1. Ten pts were ER and/or PR
positive. No grade 4 toxicities have been reported. Grade 3 toxicity
includes headaches (2 pts), vomiting (1 pt), constipation (2 pts),
fatigue (2 pts), nonneutropenic fever (1 pt). We have observed 1 CR, 1
PR, 6 MR, and 3 SD. Four pts did not respond to treatment. One pt was
not evaluable for response. Median duration of response in brain was
10.5 weeks (range, 6-48+ wks). Two pts with SD and 2 pts with MR had
previously received whole brain radiation therapy. Three pts were taken
off the study because of progression of disease outside the brain
including the pt who had a CR in brain but progressed systemically. Four
pts are actively being treated in the study.
Conclusions: The combination of C and T seems to be active and well
tolerated for the treatment of brain metastases from breast carcinoma.
Further studies should include the evaluation of this combination with
radiation and as adjuvant therapy in those pts who are at high risk of
developing brain metastases.
Wednesday, December 8, 2004 4:30 PM
What this means to me is that 11 out of 16 had SOME kind of response. A very small study indeed, yet...... I can be one of the responders, yes?
xoxoxopattyz
And and and....I can't remember if I posted this info before. very large <<sigh>> here.
ok. here it is and you can especially note the "RESULTS:" ( CR= complete response PR= partial response SD= stable disease MD=mixed response )
SABCS ABSTRACT: [San Antonio Breast Cancer Symposium] [1079] Phase I
study of capecitabine © in combination with temozolomide (T) in the
treatment of patients with brain metastases from breast carcinoma.
Rivera E, Valero V, Francis D, Brewster A, Royce M, Esteva F, Murray JL,
Pusztai L, Hortobagyi GN.. The University of Texas M.D. Anderson Cancer
Center, Houston, TX
Background: T is an oral alkylating agent that is currently being used
for the treatment of primary brain tumors due to its ability to cross
the blood-brain barrier. C has been approved for use in the treatment of
metastatic breast cancer patients who have failed anthracyclines and
taxanes. It is well known that C crosses the blood-brain barrier and has
activity in the brain. Options are limited for patients with brain
metastases.
Materials and Methods: We evaluated the activity of both drugs in
combination for the treatment of brain metastases not amenable to
surgery. Patients were allowed in the study if they had new onset brain
metastases from breast cancer, had declined radiation therapy, and were
neurologically stable. They were also eligible if they had evidence of
recurrence or progression of brain metastases after whole brain or
stereotactic radiation therapy. C was started at 1800
mg/m2 in 2 divided doses. T was given at a starting dose of 75 mg/m2 in
one daily dose. Each drug was given concomitantly every day for 5
days (day 1-5) followed by 2 days of rest and restarted again for an
additional 5 days (days 8-12). Each cycle was repeated every 21
days. We have enrolled a total of 16 pts — 6 pts at dose level 0
(C/T — 1800/75), 6 pts at dose level 1 (C/T — 1800/100), and 4 pts
at dose level 2
(n/T — 2000/100).
Results: Five pts had recurrent brain metastases and had been previously
treated with radiation therapy. The median age is 51 yrs (range, 32-77).
All pts had a Zubrod performance status < 1. Ten pts were ER and/or PR
positive. No grade 4 toxicities have been reported. Grade 3 toxicity
includes headaches (2 pts), vomiting (1 pt), constipation (2 pts),
fatigue (2 pts), nonneutropenic fever (1 pt). We have observed 1 CR, 1
PR, 6 MR, and 3 SD. Four pts did not respond to treatment. One pt was
not evaluable for response. Median duration of response in brain was
10.5 weeks (range, 6-48+ wks). Two pts with SD and 2 pts with MR had
previously received whole brain radiation therapy. Three pts were taken
off the study because of progression of disease outside the brain
including the pt who had a CR in brain but progressed systemically. Four
pts are actively being treated in the study.
Conclusions: The combination of C and T seems to be active and well
tolerated for the treatment of brain metastases from breast carcinoma.
Further studies should include the evaluation of this combination with
radiation and as adjuvant therapy in those pts who are at high risk of
developing brain metastases.
Wednesday, December 8, 2004 4:30 PM
What this means to me is that 11 out of 16 had SOME kind of response. A very small study indeed, yet...... I can be one of the responders, yes?
xoxoxopattyz